pembrolizumab and berahyaluronidase alfa-pmph
| Brand name | Keytruda Qlex |
|---|---|
| Active ingredient | pembrolizumab and berahyaluronidase alfa-pmph |
| Strength | 790MG/4.8ML; 9,600UNITS/4.8ML (165MG/2,000UNITS/ML) |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | September 2025 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.